Novartis Casts Nets Globally To Snap Up Best Assets
The Swiss major’s business development chief Susanne Kreutz tells Scrip that geography is no barrier for her team in the search for promising licensing deals or bolt-on acquisitions.
You may also be interested in...
Money may have become too tight to mention for many biotechs and the IPO window in Europe is not just shut but boarded up. However, big pharma’s need to replenish the pipeline has become urgent and the major players are looking to tap into the continent’s early-stage companies which are driving innovation and provide them with much-needed cash.
Plus deals involving Abliva/Owl, Selecta/Cartesian, Novo Nordisk/Genevant, AbbVie/Aldeyra and more.
A Phase III hit moves atrasentan a step closer to the market but the drug will have to sell very well to justify the billions Novartis paid for its originator.